Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cysticercosis
Reports outline cysticercosis study findings from National Autonomous University
July 23rd, 2008
"In search of reducing vaccine production costs', a recombinant M13 phage version of the anti-cysticercosis tripeptide vaccine (S3Pvac) was developed. The efficacy of S3Pvac-Phage vs. placebo was evaluated in a randomized trial that included 1047 rural pigs in 16 villages of Central Mexico," scientists writing in the journal Vaccine report. "Three to five months after vaccination 530 pigs were examined by tongue inspection. At 5-27 months of age, 331 pigs (197 vaccinated/134 controls) were inspected at necropsy," wrote J. Morales and colleagues, National Autonomous University. The researchers concluded: "Vaccination reduced 70% the frequency...
Source: Vaccine Weekly (2008-07-23)
|
